Oculis publishes insider RSU‑vesting disclosure

The Switzerland‑based biotech company Oculis Holding AG (Oculis) announced on Nov. 28, 2025 that it has published a “notification of transactions by persons discharging managerial responsibilities” (PDMR). The filing relates to the vesting and settlement of restricted stock units (RSUs) that had previously been granted to one of its directors, Arshad Khanani. The notice indicates the RSU‑vesting occurred on Nov. 25, 2025. However, the company did not disclose the number of shares vested or the monetary value resulting from the settlement. While such disclosures are typical as part of insider filings under securities regulation, this particular announcement offers limited detail — simply the name of the director and the date of vesting — leaving the direct impact on shareholder value unclear. Nonetheless, the update keeps investors informed about internal equity compensation events at Oculis. #Oculis #RSU #InsiderDisclosure #BiotechNews #SlimScan #GrowthStocks #CANSLIM